Technical Analysis for AUPH - Aurinia Pharmaceuticals Inc
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
14.84 | 2.34% | 0.34 |
AUPH closed up 2.34 percent on Wednesday, April 8, 2020, on 52 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Up |
| Historical AUPH trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Bearish Engulfing | Bearish | 2.34% | |
| Stochastic Sell Signal | Bearish | 2.34% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 2.34% | |
| Outside Day | Range Expansion | 2.34% |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/14/2019
- Sector: Healthcare
- Industry: Biotechnology
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, is engaged in the development of a therapeutic drug to treat autoimmune diseases in Canada. The company's lead drug includes Voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis. It has a development and license agreement with 3SBio Inc. for the clinical development, registration, and commercialization of voclosporin in China; and licensing and collaboration agreement with Vifor Pharma for the treatment of lupus and various proteinuric nephrology indications. The company was formerly known as Isotechnika Pharma Inc. and changed its name to Aurinia Pharmaceuticals Inc. in October 2013. Aurinia Pharmaceuticals Inc. was founded in 1993 and is headquartered in Victoria, Canada.
Medicine Biopharmaceutical Life Sciences Drugs Autoimmune Diseases Immunosuppressants Peptides Lupus Lupus Nephritis Treatment Of Lupus
Medicine Biopharmaceutical Life Sciences Drugs Autoimmune Diseases Immunosuppressants Peptides Lupus Lupus Nephritis Treatment Of Lupus
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 21.93 |
| 52 Week Low | 3.52 |
| Average Volume | 1,628,380 |
| 200-Day Moving Average | 10.91 |
| 50-Day Moving Average | 16.45 |
| 20-Day Moving Average | 13.48 |
| 10-Day Moving Average | 14.49 |
| Average True Range | 1.12 |
| ADX | 21.68 |
| +DI | 17.46 |
| -DI | 19.38 |
| Chandelier Exit (Long, 3 ATRs ) | 13.06 |
| Chandelier Exit (Short, 3 ATRs ) | 13.20 |
| Upper Bollinger Band | 15.92 |
| Lower Bollinger Band | 11.03 |
| Percent B (%b) | 0.78 |
| BandWidth | 36.22 |
| MACD Line | -0.38 |
| MACD Signal Line | -0.73 |
| MACD Histogram | 0.3447 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 15.53 | ||||
| Resistance 3 (R3) | 15.48 | 15.20 | 15.42 | ||
| Resistance 2 (R2) | 15.20 | 15.02 | 15.23 | 15.38 | |
| Resistance 1 (R1) | 15.02 | 14.92 | 15.11 | 15.07 | 15.34 |
| Pivot Point | 14.74 | 14.74 | 14.79 | 14.77 | 14.74 |
| Support 1 (S1) | 14.56 | 14.56 | 14.65 | 14.61 | 14.34 |
| Support 2 (S2) | 14.28 | 14.46 | 14.31 | 14.30 | |
| Support 3 (S3) | 14.10 | 14.28 | 14.27 | ||
| Support 4 (S4) | 14.15 |
